Progress to Further Commercialisation - updates, page-12

Excellent video re content , presenter ok but content good. I think this share really has excellent potential in terms of SP now the foundations for a suite of Ca diagnostics and some treatments is really exciting with good scope for partnerships. I have been a holder since 2018 and I know there are lots who have held for much longer but slowly all the ducks seem to be lining up and I am not expecting much SP action in early 2021 but mid to late 2021 is when I hope things start to appreciate, especially when Griffith have verified the data for the initial Bard1 test, should be interesting next 12 months,